Interstitial Lung Disease.
10.4046/trd.2011.71.3.163
- Author:
Man Pyo CHUNG
1
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. mp.chung@samsung.com
- Publication Type:Review
- Keywords:
Lung Disease, Interstitial;
Idiopathic Pulmonary Fibrosis;
Pirfenidone
- MeSH:
Benzamides;
Biomarkers;
Emphysema;
Hand;
Idiopathic Pulmonary Fibrosis;
Interferon-gamma;
Lung Diseases, Interstitial;
Lymphangioleiomyomatosis;
Piperazines;
Pulmonary Fibrosis;
Purines;
Pyridones;
Pyrimidines;
Sirolimus;
Sulfones;
Imatinib Mesylate;
Sildenafil Citrate
- From:Tuberculosis and Respiratory Diseases
2011;71(3):163-171
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recently published articles on interstitial lung disease (ILD) have focused on the accurate diagnosis of idiopathic pulmonary fibrosis (IPF), serum biomarkers, acute exacerbation of IPF, the prognostic factors of ILD and the trial of new treatment. In particular, reports on the serum biomarkers such as CC-chemokine ligand 18, surfactant protein, circulating fibrocytes, and acute exacerbation of IPF are sufficient to be mentioned here. Pirfenidone therapy is the most important trial for the treatment of IPF. Other newer treatment trials such as interferon-gamma, sildenafil and imatinib have been reported to be unsuccessful. On the other hand, the sirolimus trial for lymphangioleiomyomatosis is promising. Combined pulmonary fibrosis and emphysema and IgG4-related disease are established to be the new disease entities of ILD.
